Everist Genomics (EGI) has established a joint-venture company with the Manipal Group. The joint venture will market EGI’s portfolio of diagnostic, prognostic, and therapeutic selection technologies in India. Over 350 cardiologists attended a medical conference organized by one of India’s leading cardiac centers, Medanta Hospital in Delhi, at which EGI’s two new mobile health (mHealth) diagnostic systems for cardiovascular disease, AngioDefender and CardioDefender were introduced to physicians attending the conference. Over 300 physicians registered on a waiting list to receive EGI’s devices as they become available in India

AngioDefender and CardioDefender integrate novel sensor technology with mobile digital services, smartphones and other mobile devices to provide flexible monitoring and diagnosis of cardiovascular conditions that traditionally have been limited to observation through legacy hospital diagnostic systems.

“The leading cause of death in India is cardiovascular disease, occurring 5 to 10 years earlier than in the west with incidence on the rise,” said Ravi Kasliwal, chairman of clinical and preventive cardiology at Medanta Heart Institute, as part of his introduction of EGI at the medical conference. “I believe by leveraging mobile service solutions these novel diagnostic systems have a strong potential to improve clinical management of CVD while creating efficiencies in cost and time spent in the healthcare setting.”

The joint venture will enable key market access to EGI’s product pipeline through Manipal’s broad network of health care operations, which includes 15 hospitals, 9 primary care clinics, and 55 community health centers. The partnership also leverages Manipal’s strong background in medical products, commercially valuable infrastructure and capabilities within the India region.

In addition to EGI’s cardiovascular franchise, the joint venture will also commercialize EGI’s companion diagnostics and prognostics portfolio for cancer, a unique combination of four molecular assays designed to help physicians personalize treatment for cancer patients. The portfolio currently provides testing relevant to colorectal and uterine cancer and will be expanded to include other indications in the future.

Source: Everist Genomics Inc